Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: A methodological approach under serum-free culture conditions

Scandinavian Journal of Immunology

Volumn 62, Issue 1, 2005, Pages 86-98

  Kufner, S ^a   Zitzelsberger, H ^b   Kroell, T ^a   Pelka Fleischer, R ^a   Salem, A ^a   De Valle, F ^c   Schweiger, C ^c   Nuessler, V ^d   Schmid, C ^a   Kolb, H J ^a   Schmetzer, H M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LEUKEMIA ANTIGEN; LYMPHOCYTE SURFACE MARKER; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD CELL; BONE MARROW CELL; CELL CULTURE; CELL MATURATION; CELL PROLIFERATION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOGENETICS; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; LEUKEMIA CELL; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINATION;

ACUTE DISEASE; ADULT; AGED; ANTIGENS, CD; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; LEUKEMIA, MYELOID; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 22644432727     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01630.x     Document Type: Article

References (49)

1. Giles FJ, Keating A, Goldstone AH, Avivi I, Willmann CL, Kantarjian HM. Acute myeloid leukemia. Hematology 2002;1:73-110.
2. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000;243:59-75.
3. Buechner T, Hiddemann W, Berdel WE et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003;21:4496-504.
4. Brossart P. Dendritic cells in vaccination therapies of malignant diseases. Transfus Apheresis Sci 2002;27:183-6.
5. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-6.
6. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from the bench to bedside. Nat Med 2001;7:761-5.
7. Claxton DF, McMannis J, Champlin R, Choudhury A. Therapeutic potenial of leukemia-derived dendritic cells: Preclinical and clinical progress. Crit Rev Immunol 2001;21:147-55.
8. Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. Immunology 2002;107:20-7.
9. Stripecke R, Levine AM, Pullarkat V, Cardoso AA. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002;16:1974-83.
10. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor á. II. Functional analysis. Blood 1997;4:1458-70.
11. Choudhury A, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999;93:780-6
12. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000;49:152-6.
13. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
14. Bene MC, Bernier M, Castoldi G et al. for the European Group for the Immunological Classification of Leukemias (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783-8.
15. Hessel H, Mittermueller J, Zitzelsberger H, Weier HU, Bauchinger M. Combined immunophenotyping and FISH with sex chromosome-specific DNA probes for the detection of chimerism in epidermal Langerhans cells after sex-mismatched bone marrow transplantation. Histochem Cell Biol 1996;106:481-5.
16. Koehler T, Plettig R, Wetzstein W et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 2000;18:139-47.
17. Nguyen XD, Eichler H, Dugrillon A, Piechaczek C, Braun M, Klüter H. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Immunol Methods 2003;9281:1-12.
18. Kienzle N, Olver S, Buttigieg K, Kelso A. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J Immunol Methods 2002;267 (2):99-108.
19. Appelbaum FR. New targets for therapy in acute myeloid leukemia. Leukemia 2003;17:492-5.
20. Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2002;43:2125-31.
21. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003;52:328-37.
22. Balaian L, Ball ED. Direct effect of bispecific anti-CD33 × anti-CD64 antibody on proliferation and signaling in myeloid cells. Leuk Res 2001;25:1115-25.
23. Song LP, Cheng JL, Wang XB et al. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003;35:503-10.
24. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 1991;254:1643-7.
25. Brossart P, Grunebach F, Stuhler G et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4238-47.
26. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47.
27. Wang L, Chen S, Liu Y et al. The function of dendritic cells derived from chronic myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000;8:161-5.
28. Strobl H, Bello-Fernandez C, Riedl E et al. flt3 ligand in cooperation with transforming growth factor-beta 1 potentiates in vitro development of Langerhans-type dendritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 1997;90:1425-34.
29. Luft T, Jefford M, Luetjens P et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific subsets. Blood 2002;100:1362-72.
30. Suen Y, Lee SM, Aono F et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001;3:365-75.
31. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol 1999;29:2567-78.
32. Bai L, Feuerer M, Beckhove P, Umansky V, Schirrmacher V. Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells. Int J Oncol 2002;20:247-53.
33. Stein GM, Bussing A, Schietzel M. Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res 2002;22:4215-9.
34. Loudovaris M, Hansen M, Suen Y, Lee SM, Casing P, Bender JG. Differential effects of autologous serum on CD34 (+) or monocyte-derived dendritic cells. J Hematother Stem Cell Res 2001;10:569-78.
35. Houtenbos I, Westers TM, Stam AG et al. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol Immunother 2003;52:455-62.
36. Panoskaltsis N, Belanger TJ, Liesveld JL, Abboud CN. Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. Leuk Res 2002;26:191-201.
37. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003;170:4069-76.
38. Woiciechowsky A, Regn S, Kolb H-I, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001;15:246-55.
39. Westers TM, Stam AGM, Scheper RJ et al. Rapid generation of antigen-presenting cells from leukemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother 2003;52:17-27.
40. Bruserud O, Gjertsen BT, von Volkman HL. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media, studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res 2000;9:923-32.
41. Oehler L, Berer A, Kollars M et al. Culture requirements for induction of dendritic cell differentiation in acute myeloid leukemia. Ann Hematol 2000;79:355-62.
42. Boyer MW, Waller EK, Bray RA et al. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia 2000;14:412-8.
43. Mohty M, Isnardon D, Blaise D et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 2002;16:2267-74.
44. Harrison BD, Adams JA, Briggs M, Brereton ML, Liu Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by 'leukemic dendritic cells' derived from blasts cells in acute myeloid leukemia. Blood 2001;97:2764-71.
45. Narita M, Takahashi M, Liu A et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp Hematol 2001;29:709-19.
46. Santiago-Schwarz F, Coppock DL, Hindenburg AA, Kern J. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood 1994;84:3054-62.
47. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002;2:982-7.
48. Westermann J, Kopp J, van Lessen A et al. Dendritic cells vaccination in BCR/ABL-positive chronic myeloid leukemia - final results of a phase I/II ASH (Abstract, 2004:2934).
49. Li L, Reinhard D, Hus I, Rolinski J, Dmoszynska A, Wiesneth M, Dohner H, Schmitt M. Dendritic Cells (DC) Generated from AML blasts express leukemia associated antigens eliciting specific cytotoxic T cell Responses in the autologus host after DC vaccination (Abstract, 2004:1812).